Regarding the IHC study of merlin, which has been recognized as challenging with currently available antibodies for merlin, a recent study indicated that the expression of merlin was absent in 52% of all pleural mesotheliomas and 70% of non-epithelioid tumors (Chapel et al., 2022). The gene discussed is NF2; the disease is pleural mesothelioma.